SCHEMBL14727019

SCHEMBL14727019

CCOC(=O)[C@H]1C[C@@H]1c1ncc(C)cc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 1/20 0.39
MAP3K5 Q99683 1/20 0.36
CA1 P00915 6/20 0.36
CA2 P00918 6/20 0.36
CA9 Q16790 5/20 0.36
CA12 O43570 4/20 0.36
ALDH1A1 P00352 3/20 0.34
TDP1 Q9NUW8 1/20 0.34
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 2/20 0.33
MAPT P10636 2/20 0.33
MEN1 O00255 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
PKM P14618 1/20 0.33
TPH1 P17752 1/20 0.33
POLB P06746 1/20 0.33
TSHR P16473 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14727023 1.00 CXCR2 (0.39) CXCR2MAP3K5CA1CA2CA9
SCHEMBL14721510 1.00 CXCR2 (0.39) CXCR2MAP3K5CA1CA2CA9
SCHEMBL30181751 0.87 TDP1 (0.41) CXCR2MAP3K5CA1CA2CA9
SCHEMBL1138191 0.76 L3MBTL1 (0.48) CA1CA2CA9CA12ALDH1A1
SCHEMBL29302286 0.76 CXCR2 (0.45) CXCR2MAP3K5CA1CA2CA9
SCHEMBL31658589 0.76 CXCR2 (0.45) CXCR2MAP3K5CA1CA2CA9
SCHEMBL12035557 0.75 CA1 (0.40) CXCR2CA1CA2CA9CA12
SCHEMBL22654459 0.74 CXCR2 (0.36) CXCR2MAP3K5CA1CA2CA9
SCHEMBL21236161 0.74 CXCR2 (0.36) CXCR2MAP3K5CA1CA2CA9
SCHEMBL21236532 0.74 CA1 (0.41) CXCR2MAP3K5CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2748151-B1 PYRIMIDINE PDE10 INHIBITORS MERCK SHARP & DOHME (US) 2016-03-16 EP disclosed
US-9062059-B2 Pyrimidine PDE10 inhibitors MERCK SHARP & DOHME CORP. (US) 2015-06-23 US disclosed
US-9062059-B2 Pyrimidine PDE10 inhibitors MERCK SHARP & DOHME CORP. (US) 2015-06-23 US disclosed
US-20140228368-A1 PYRIMIDINE PDE10 INHIBITORS MERCK SHARP & DOHME LLC 2014-08-14 US disclosed
US-20140228368-A1 PYRIMIDINE PDE10 INHIBITORS MERCK SHARP & DOHME LLC 2014-08-14 US disclosed
WO-2013028590-A1 PYRIMIDINE PDE10 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140228368-A1 PYRIMIDINE PDE10 INHIBITORS PDE12, PDE10A, PDE11A CXCR2 1696/4885MAP3K5 1151/4885CA1 4464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.